Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Effects of the lifestyle habits in breast cancer transcriptional regulation.

Pérez-Solis MA, Maya-Nuñez G, Casas-González P, Olivares A, Aguilar-Rojas A.

Cancer Cell Int. 2016 Feb 13;16:7. doi: 10.1186/s12935-016-0284-7. eCollection 2016. Review.

2.

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.

Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES.

Breast Cancer Res Treat. 2015 Apr;150(3):569-79. doi: 10.1007/s10549-015-3359-6. Epub 2015 Apr 2.

3.

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, Ganju RK.

Mol Oncol. 2015 Apr;9(4):906-19. doi: 10.1016/j.molonc.2014.12.010. Epub 2015 Jan 19.

4.

EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Mill CP, Chester JA, Riese DJ 2nd.

Breast Cancer (Dove Med Press). 2009 Oct 5;1:31-8. Review.

5.

β1-Integrin via NF-κB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer.

Nam JM, Ahmed KM, Costes S, Zhang H, Onodera Y, Olshen AB, Hatanaka KC, Kinoshita R, Ishikawa M, Sabe H, Shirato H, Park CC.

Breast Cancer Res. 2013;15(4):R60.

6.

Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer.

Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, Alahari SK.

Cancer Res. 2013 May 1;73(9):2884-96. doi: 10.1158/0008-5472.CAN-12-2162. Epub 2013 Jan 21.

7.

Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer.

Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S.

PLoS One. 2012;7(10):e46823. doi: 10.1371/journal.pone.0046823. Epub 2012 Oct 4.

8.

Regulation of NF-κB by the CARD proteins.

Jiang C, Lin X.

Immunol Rev. 2012 Mar;246(1):141-53. doi: 10.1111/j.1600-065X.2012.01110.x. Review.

9.

FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling.

Wang J, Ray PS, Sim MS, Zhou XZ, Lu KP, Lee AV, Lin X, Bagaria SP, Giuliano AE, Cui X.

Oncogene. 2012 Nov 8;31(45):4798-802. doi: 10.1038/onc.2011.635. Epub 2012 Jan 16.

10.

Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4.

Manu KA, Shanmugam MK, Rajendran P, Li F, Ramachandran L, Hay HS, Kannaiyan R, Swamy SN, Vali S, Kapoor S, Ramesh B, Bist P, Koay ES, Lim LH, Ahn KS, Kumar AP, Sethi G.

Mol Cancer. 2011 Sep 1;10:107. doi: 10.1186/1476-4598-10-107.

11.

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.

Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, Chi CW, Chen DR.

Evid Based Complement Alternat Med. 2012;2012:486568. doi: 10.1155/2012/486568. Epub 2011 Jun 6.

12.

Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer.

Wu J, Omene C, Karkoszka J, Bosland M, Eckard J, Klein CB, Frenkel K.

Cancer Lett. 2011 Sep 1;308(1):43-53. doi: 10.1016/j.canlet.2011.04.012. Epub 2011 May 13.

13.

FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB.

Guo C, Stark GR.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7968-73. doi: 10.1073/pnas.1105369108. Epub 2011 Apr 25.

14.

CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression.

Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC, Lin X.

Cancer Res. 2011 Mar 15;71(6):2183-92. doi: 10.1158/0008-5472.CAN-10-3626.

15.

Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition.

Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu N, Li S, Wen G, Zhang C, Dong W, Wang X, Dou QP, Liu J.

Eur J Pharmacol. 2011 May 11;658(2-3):242-7. doi: 10.1016/j.ejphar.2011.02.043. Epub 2011 Mar 24.

16.

Angiocidin inhibits breast cancer proliferation through activation of epidermal growth factor receptor and nuclear factor kappa (NF-ĸB).

Godek J, Sargiannidou I, Patel S, Hurd L, Rothman VL, Tuszynski GP.

Exp Mol Pathol. 2011 Jun;90(3):244-51. doi: 10.1016/j.yexmp.2011.01.002. Epub 2011 Jan 15.

17.

NF-κB signaling pathways regulated by CARMA family of scaffold proteins.

Blonska M, Lin X.

Cell Res. 2011 Jan;21(1):55-70. doi: 10.1038/cr.2010.182. Epub 2010 Dec 28. Review.

18.

Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden.

Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, Yull FE.

Oncogene. 2011 Mar 24;30(12):1402-12. doi: 10.1038/onc.2010.521. Epub 2010 Nov 15.

19.

Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor.

Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, Chaturvedi MM, Aggarwal BB.

J Mol Med (Berl). 2010 Dec;88(12):1243-53. doi: 10.1007/s00109-010-0669-3. Epub 2010 Aug 27. Erratum in: J Mol Med (Berl). 2013 Mar;91(3):407-8.

20.

Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity.

Roth I, Leroy V, Kwon HM, Martin PY, Féraille E, Hasler U.

Mol Biol Cell. 2010 Oct 1;21(19):3459-74. doi: 10.1091/mbc.E10-02-0133. Epub 2010 Aug 4.

Items per page

Supplemental Content

Write to the Help Desk